A First-in-Human Safety Trial of MTX-463

MTX-463-I101: A Phase 1 Randomized, Double-Blind, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of MTX-463 in Healthy Adults

A randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-463 administered in healthy adults.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Biological: MTX-463; Other: Placebo

Detailed Description

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-463 administered in healthy adults.

SAD Portion

The SAD portion of the study will consist of 4 planned dosing cohorts each comprising 8 healthy participants. The starting dose will be 4 mg/kg (Cohort 1) with subsequent planned doses of 8 mg/kg (Cohort 2), 16 mg/kg (Cohort 3), and 30 mg/kg (Cohort 4). Planned doses may be adjusted in response to the data. Additional participants and/or additional dosing cohorts may be added as needed based on the data.

Within each cohort, participants will be randomly assigned to receive MTX-463 or matched placebo. The first 2 participants (sentinel participants) within each cohort will be randomized 1:1 to receive MTX-463 or placebo on Day 1. These participants will be monitored for 24 hours, and after review of the safety data from both participants and approval by the study Investigator and Sponsor's responsible medical officer (SRMO), the additional 6 participants will be randomized to study drug (n=5 MTX-463; n=1 placebo).

Each participant will undergo assessments at specified timepoints on Days 1 through 60. End-of-Study (EOS) procedures will be completed on Day 28 or upon early termination (ET). An End-of-Follow-up (EOF) assessment of PK and ADA will be completed on Day 60.

MAD Portion

The MAD portion of the study will consist of 3 planned dosing cohorts. Each cohort will comprise 8 healthy participants (n=6 MTX-463; n=2 placebo). The starting dose will be a 6.6 mg/kg loading dose and 4 mg/kg maintenance doses (Cohort 1) with subsequent planned doses of a 13 mg/kg loading dose and 8 mg/kg maintenance doses (Cohort 2), and a 27 mg/kg loading dose and 16 mg/kg maintenance doses (Cohort 3). Planned doses may be adjusted in response to the data. Additional participants and/or additional dosing cohorts may be added as needed based on the data.

On Day 1, participants will be randomized to receive either MTX-463 or matched placebo. The randomized participants will receive a single loading dose on Day 1 followed by 2 maintenance doses of study drug on Day 8 and Day 22. Participants will be housed inpatient from Day -1 through post-dose observation on Day 8 and from Day 21 through assessments on Day 29. All other visits will be conducted in the outpatient setting. Each participant will undergo assessments at specified timepoints on Days 1 through 82. End-of-study procedures will be completed on Day 50, or upon ET. An EOF assessment of PK and ADA will be completed on Day 82.

Safety and tolerability of MTX-463 will be reviewed through Day 29 by the study Investigator and SRMO to inform dose escalation decisions for the next dose cohort.

Additional cohorts for the SAD and MAD portions of the study may be added as needed to potentially explore lower doses.

• Study Type: Interventional
• Enrollment (Actual): 56
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Utah
    • Salt Lake City, Utah, United States, 84124
      • ICON

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Key Inclusion Criteria:

• All genders, ages 18 to 60 years, inclusive
• Willing and able to complete all protocol-required study visits and procedures
• Non-smoker and has not used nicotine- or cotinine-containing products (including tobacco, nicotine gum, patches, and e-cigarettes) for at least 90 days before Screening and until the last study visit
• Willing to refrain from marijuana- or cannabinol-containing products for 90 days before Screening and until the last study visit
• Willing to refrain from ingestion of alcohol from 7 days before Screening until the last study visit
• Agree to a highly effective method of contraception for 28 days prior to the first dose of study drug, and persist through 28 days after the last dose of study drug

Key Exclusion Criteria:

• - Any history of clinically significant lung disease as determined by the Investigator, including but not limited to asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, pulmonary embolus, or pulmonary arterial hypertension
• Any other concurrent active medical condition determined clinically significant by the Investigator
• Body mass index (BMI) >40 kg/m2
• Use of any systemic immunosuppressant medications, medications to treat diabetes, antipsychotics, anticoagulants, or other medications within 90 days of Screening
• Cancer or a history of cancer or lymphoproliferative disorder within 5 years of Screening other than adequately treated non-melanomatous skin cancers or cervical carcinoma in situ
• Current infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) as evidenced by a positive hepatitis B-surface antigen or a positive HIV test at Screening
• Currently pregnant, lactating, or planning to conceive or contribute to pregnancy during the trial and up to 28 days after the participant's last dose of study drug, if applicable
• History of severe depression, psychosis, or suicidal ideation within 5 years of Screening
• History of substance use disorder as specified in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, within 1 year of Screening
• Any clinically significant disease or laboratory abnormality detected at Screening that might interfere with a participant's ability to complete the study, on-study evaluations, or participant safety
• Any surgical procedure, including planned procedures within 12 weeks of Screening
• Participation in another research study of an investigational agent within 30 days of Screening or 5 half-lives of the agent, whichever is longer

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Other: Placebo; Matching Placebo-- Normal Saline
Experimental: MTX-463	Biological: MTX-463; MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases and malignancies.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Treatment-Related Adverse Events in healthy volunteers	Clinical Safety Labs are collected, and Adverse Events are assessed in both inpatient and outpatient clinic visits	Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
MTX-463 PK by dose will be evaluated for Cmax, as feasible	Blood serum samples will be collected at protocol-specified timepoints throughout the study	Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
Serum sample results will be summarized for presence of Anti-Drug Antibodies during the SAD and MAD portions of the study.	Blood serum samples will be collected at protocol-specified timepoints throughout the study to assess for the presence and titer (if applicable) of Anti-Drug Antibodies.	Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
MTX-463 PK by dose will be evaluated for AUC0-t, as feasible.	Blood serum samples will be collected at protocol-specified timepoints throughout the study	Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
MTX-463 PK by dose will be evaluated for AUC0-tau (MAD only), as feasible	Blood serum samples will be collected at protocol-specified timepoints throughout the study	Through Day 82 (MAD Cohort)
MTX-463 PK by dose will be evaluated for AUC0-∞, as feasible	Blood serum samples will be collected at protocol-specified timepoints throughout the study	Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Blood serum samples will be collected to determine the level of WISP1 engagement of MTX-463 in healthy adult participants	These assessments will be summarized as: Change from Baseline in total WISP1 levels; Change from Baseline in free WISP1 levels	Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
To assess the effect of baseline body mass index (BMI) on total and free WISP1 levels	Baseline levels and change from Baseline of the total and free WISP1 levels will be compared in those with BMIs ≥30 kg/m2 to those with BMIs <30 kg/m2.	Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
To assess the effect of MTX-463 on PD biomarker PRO-C3 for fibrosis in healthy adult participants	Change from Baseline in fibrosis biomarker PRO-C3 will be evaluated.	Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker PRO-C6 for fibrosis in healthy adult participants	Change from Baseline in fibrosis biomarker PRO-C6 will be evaluated.	Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker C7M for fibrosis in healthy adult participants	Change from Baseline in fibrosis biomarker C7M will be evaluated.	Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker IFN-γ for inflammation	Baseline levels and change from Baseline of PD biomarker IFN-γ for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs <30 kg/m2.	Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker IL-1β for inflammation	Baseline levels and change from Baseline of PD biomarker IL-1β for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs <30 kg/m2.	Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker IL-2 for inflammation	Baseline levels and change from Baseline of PD biomarker IL-2 for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs <30 kg/m2.	Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker IL-4 for inflammation	Baseline levels and change from Baseline of PD biomarker IL-4 for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs <30 kg/m2.	Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker IL-6 for inflammation	Baseline levels and change from Baseline of PD biomarker IL-6 for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs <30 kg/m2.	Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker IL-10 for inflammation	Baseline levels and change from Baseline of PD biomarker IL-10 for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs <30 kg/m2.	Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker IL-12p70 for inflammation	Baseline levels and change from Baseline of PD biomarker IL-12p70 for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs <30 kg/m2.	Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker IL-17A for inflammation	Baseline levels and change from Baseline of PD biomarker IL-17A for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs <30 kg/m2.	Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker TNF-α for inflammation	Baseline levels and change from Baseline of PD biomarker TNF-α for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs <30 kg/m2.	Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker IFN-γ for inflammation in healthy adult participants	Change from Baseline in pro-inflammatory biomarker IFN-γ will be evaluated.	Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker IL-1β for inflammation in healthy adult participants	Change from Baseline in pro-inflammatory biomarker IL-1β will be evaluated.	Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker IL-2 for inflammation in healthy adult participants	Change from Baseline in pro-inflammatory biomarker IL-2 will be evaluated.	Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker IL-4 for inflammation in healthy adult participants	Change from Baseline in pro-inflammatory biomarker IL-4 will be evaluated.	Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker IL-6 for inflammation in healthy adult participants	Change from Baseline in pro-inflammatory biomarker IL-6 will be evaluated.	Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker IL-10 for inflammation in healthy adult participants	Change from Baseline in pro-inflammatory biomarker IL-10 will be evaluated.	Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker IL-12p70 for inflammation in healthy adult participants	Change from Baseline in pro-inflammatory biomarker IL-12p70 will be evaluated.	Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker IL-17A for inflammation in healthy adult participants	Change from Baseline in pro-inflammatory biomarker IL-17A will be evaluated.	Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker TNF-α for inflammation in healthy adult participants	Change from Baseline in pro-inflammatory biomarker TNF-α will be evaluated.	Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker PRO-C3 for fibrosis	Baseline levels and change from Baseline of PD biomarker PRO-C3 for fibrosis will be compared in those with BMIs ≥30 kg/m2 to those with BMIs <30 kg/m2.	Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker PRO-C6 for fibrosis	Baseline levels and change from Baseline of PD biomarker PRO-C6 for fibrosis will be compared in those with BMIs ≥30 kg/m2 to those with BMIs <30 kg/m2.	Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker C7M for fibrosis	Baseline levels and change from Baseline of PD biomarker C7M for fibrosis will be compared in those with BMIs ≥30 kg/m2 to those with BMIs <30 kg/m2.	Through Day 36 (MAD Cohort)

Collaborators and Investigators

• Sponsor: Mediar Therapeutics
• Collaborators: ICON plc
• Investigators: Principal Investigator: Ahad Sabet, MD, ICON plc; Study Director: Jeffrey Bornstein, MD, Mediar Therapeutics

Study record dates

Study Major Dates

• Study Start (Actual): April 15, 2024
• Primary Completion (Actual): November 15, 2024
• Study Completion (Actual): November 15, 2024

Study Registration Dates

• First Submitted: April 22, 2024
• First Submitted That Met QC Criteria: May 2, 2024
• First Posted (Actual): May 6, 2024

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 16, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Keywords: SAD; MAD; ADULT; HEALTHY VOLUNTEER; MTX-463-I101; MTX-463; WISP-1
• Other Study ID Numbers: MTX-463-I101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No